Literature DB >> 17439838

Immunohistochemical evaluation of necrotic malignant melanomas.

Daisuke Nonaka1, Jordan Laser, Rachel Tucker, Jonathan Melamed.   

Abstract

We evaluated 35 cases of malignant melanomas with substantial necrosis immunostained with S-100, HMB-45, Melan-A, tyrosinase, PNL2, and microphthalmia transcription factor (MITF). Staining patterns were evaluated in viable and necrotic areas of the tumors. S-100 was the most sensitive marker (97%) in the viable tumors, but necrotic areas demonstrated nonspecific staining. Viable tumors stained variably for HMB-45 (25 [71%]), Melan-A (28 [80%]), tyrosinase (30 [86%]), and PNL2 (23 [66%]). Necrotic areas focally reacted to the same antibodies. The necrotic areas that retained immunoreactivity for these markers corresponded to areas where the outline of the tumor cells could still be recognized as ghost cells on the H&E-stained section. Areas that showed complete coagulative necrosis were negative for melanoma markers. MITF variably stained in the viable tumors but was completely negative in necrotic areas. Our study demonstrated that a combination of antibodies to HMB-45, tyrosinase, and PNL2 detected melanocytic differentiation in necrotic areas in 80% of cases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17439838     DOI: 10.1309/WKEN4ER9GXJ9GG31

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  2 in total

1.  KBA62 and PNL2: 2 new melanoma markers-immunohistochemical analysis of 1563 tumors including metastatic, desmoplastic, and mucosal melanomas and their mimics.

Authors:  Phyu Phyu Aung; Maarit Sarlomo-Rikala; Jerzy Lasota; Jin-Ping Lai; Zeng-Feng Wang; Markku Miettinen
Journal:  Am J Surg Pathol       Date:  2012-02       Impact factor: 6.394

2.  Expression of microphthalmia transcription factor, S100 protein, and HMB-45 in malignant melanoma and pigmented nevi.

Authors:  Jianxin Xia; Yanlong Wang; Fuqiu Li; Jinfeng Wang; Yan Mu; Xianglin Mei; Xue Li; Wenjing Zhu; Xianhua Jin; Kai Yu
Journal:  Biomed Rep       Date:  2016-08-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.